Skip to main content

Table 5 Association between exposure to different oral osteoarthritis therapies and occurrence of knee replacement

From: Impact of oral osteoarthritis therapy usage among other risk factors on knee replacement: a nested case-control study using the Osteoarthritis Initiative cohort

  Acetaminophen NSAIDs COX-2 inhibitors Narcotics Glucosamine/chondroitin sulfate
n ORb 95% CI p c n ORb 95% CI p c n ORb 95% CI p c n ORb 95% CI p c n ORb 95% CI p c
Primary analysis
 In the 3 years prior to index date (n = 521: 161 KR/360 controls)
  Exposure 1–79%a 124 1.09 (0.66–1.78) 0.745 313 1.05 (0.64–1.72) 0.839 68 1.13 (0.48–2.67) 0.784 67 1.00 (0.48–2.09) 0.995 120 0.85 (0.50–1.48) 0.573
  Exposure ≥ 80%a 14 1.11 (0.30–4.09) 0.872 44 1.66 (0.93–2.95) 0.086 21 1.15 (0.47–2.83) 0.761    ND   163 0.73 (0.43–1.23) 0.236
Secondary Analyses
 In the 2 years prior to index date (n = 642: 193 KR/449 controls)
  Exposure 1–79%a 210 1.10 (0.66–1.84) 0.722 369 0.96 (0.60–1.54) 0.853 88 1.40 (0.57–3.48) 0.465 77 1.19 (0.54–2.58) 0.670 255 0.70 (0.39–1.26) 0.235
  Exposure ≥ 80%a 20 1.46 (0.69–3.11) 0.322 58 1.41 (0.88–2.26) 0.159 27 1.18 (0.55–2.52) 0.671    ND   166 1.00 (0.65–1.55) 0.989
 In the 4 years prior to index date (n = 363: 121 KR/242 controls)
  Exposure 1–79%a 113 1.34 (0.74–2.41) 0.333 234 1.40 (0.78–2.52) 0.256 50 1.63 (0.64–4.13) 0.303 50 1.43 (0.62–3.33) 0.405 156 0.65 (0.33–1.25) 0.191
  Exposure ≥ 80%a    ND   26 1.65 (0.75–3.66) 0.215    ND     ND   83 0.63 (0.32–1.21) 0.165
 In the 5 years prior to index date (n = 228: 82 KR/146 controls)
  Exposure 1–79%a 60 1.38 (0.66–2.88) 0.397 110 1.88 (0.85–4.20) 0.121 18 1.35 (0.41–4.49) 0.623 33 1.19 (0.48–2.93) 0.706 54 0.90 (0.37–2.14) 0.803
  Exposure ≥ 80%a 15 1.66 (0.44–6.35) 0.457 45 2.27 (0.90–5.71) 0.081    ND     ND   70 0.73 (0.33–1.64) 0.445
  1. CI confidence interval, COX-2 cyclooxygenase-2, KR knee replacement, ND not determinable, n value too small, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis, OR odds ratio
  2. aCompared to the “no exposure” category
  3. bAdjusted for race, body mass index, other medication for pain, joint space width, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness, meniscal extrusion, bone marrow lesions, and Knee injury and Osteoarthritis Outcome Score (KOOS)
  4. cConditional logistic regression